Biocon may gain from a possible alliance with clinical research organisation Siro Clinpharm. Biocon will not only get access to Siro’s huge client base, but the deal will also help its subsidiary Syngene get attractive valuations. Siro offers services ranging from data management, pharmacovigilance, medical writing, bio-statistics, etc. which can bolster Biocon’s clinical trials expertise. Biocon will be able to use Siro’s client base to get more clinical trials work and thus get more projects.
Siro is a strategic fit for Biocon subsidiaries Clinigene and Syngene. Biocon is looking at listing Syngene and if Siro gets acquired and merged with Syngene, the valuations will be better. Syngene does contract research for pharmaceutical companies, while Clinigene manages clinical trials for drug companies.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.20 |
| Dr. Reddys Lab | 1307.10 |
| Cipla | 1368.95 |
| Zydus Lifesciences | 941.70 |
| Lupin | 2470.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: